Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-RA study of JTE-051 in active rheumatoid arthritis
2015-003140-39Phase 2Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing JTE-051 with Placebo (2 arms). Primary endpoint: ACR20 response at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
JTE-051
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-003140-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003140-39.